Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Senicapoc in Idiopathic Pulmonary Fibrosis: NCT06714123 Clinical Landscape Report 2026
28 September 2026
NCT06714123 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Denifanstat in Metabolic Dysfunction Associated Steatohepatitis: NCT06692283 Clinical Landscape Report 2026
28 September 2026
NCT06692283 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
NM-6606 in Metabolic Dysfunction Associated Steatohepatitis: NCT06716905 Clinical Landscape Report 2026
28 September 2026
NCT06716905 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
CAL-101 (Calluna) in Idiopathic Pulmonary Fibrosis: NCT06736990 Clinical Landscape Report 2026
28 September 2026
NCT06736990 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SB17170 in Idiopathic Pulmonary Fibrosis: NCT06747923 Clinical Landscape Report 2026
28 September 2026
NCT06747923 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ORT-247 in Amyotrophic Lateral Sclerosis: NCT06769620 Clinical Landscape Report 2026
28 September 2026
NCT06769620 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VGN-R13 in Amyotrophic Lateral Sclerosis: NCT06849609 Clinical Landscape Report 2026
28 September 2026
NCT06849609 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FHND1002 in Amyotrophic Lateral Sclerosis: NCT06782958 Clinical Landscape Report 2026
28 September 2026
NCT06782958 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Psilocybin in Pulmonary Disease, Chronic Obstructive: NCT06782724 Clinical Landscape Report 2026
28 September 2026
NCT06782724 clinical landscape for Pulmonary Disease, Chronic Obstructive: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Levocarnitine in Amyotrophic Lateral Sclerosis: NCT06849115 Clinical Landscape Report 2026
28 September 2026
NCT06849115 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHED-CM(U Factor) in Amyotrophic Lateral Sclerosis: NCT06889857 Clinical Landscape Report 2026
28 September 2026
NCT06889857 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
[18F]ACI-19626 in Alzheimer Disease: NCT06891716 Clinical Landscape Report 2026
28 September 2026
NCT06891716 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.